FairJourney Biologics
Caroline Dimech currently serves as Team Leader for Discovery and Engineering at IONTAS since February 2022. Prior to this role, Caroline was the Head of Discovery at Avacta from October 2020 to January 2022, overseeing Affimer selections and early stage screening processes. Caroline's extensive experience in biopharmaceuticals includes a significant tenure at GSK as an Investigator in Biopharm Discovery from April 2007 to October 2020, where responsibilities included antibody engineering and leading discovery campaigns. Earlier career positions include being a Research Scientist at Domantis and Cambridge Antibody Technology, focusing on antibody engineering and protein expression. Caroline Dimech earned a PhD in Molecular Pharmacology from the University of Reading and completed undergraduate studies at the University of York.
This person is not in any offices
FairJourney Biologics
FairJourney Biologics is a privately established company with an outstanding track record of biotech and biopharmaceutical partners (Merus, argenX, BMS, Bayer, among others), offering a range of assets and services on antibody discovery, engineering, production, characterization up to cell line development stages. Our naïve and immune libraries from humans, rodents and llama, together with our know-how and internal technological development allow us to contribute to the pipeline of our partners on complex targets, leading to 14 known antibodies in the clinic. More recently, FairJourney Biologics has been joined by specialists in the field such as Tariq Ghayur (formerly Abbvie) and Rene Hoet (formerly Bayer), creating a panel of available scientists as service to support complex antibody projects. From target validation up to cell line development and pre-CMC reporting, FairJourney Biologics is a one stop shop leader in antibody services. As of 2022, the company has a headcount of above 200 staff members and a track record of more than 800 projects on a variety of areas.